Skip to main content
SpringerLink
Log in
Book cover

Orphan Lung Diseases pp 391–418Cite as

Interstitial Lung Disease in Connective Tissue Diseases Other Than Systemic Sclerosis

  • Chapter
  • First Online:

Abstract

The connective tissue disorders (CTD, also called collagen vascular diseases) represent an heterogenous group of immunologically mediated inflammatory disorders with a large variety of affected organs besides the lungs. The respiratory system may be involved in all its components: airways, vessels, parenchyma, pleura, respiratory muscles, etc.… The frequency, clinical presentation, prognosis and response to therapy vary, depending on the pattern of involvement as well as on the underlying connective tissue disorders. The subject of this article is to review the interstitial lung disease (ILD) observed in patients with CTD. We will focus on the most frequent CTD: systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren’s syndrome (SS), inflammatory myopathies and mixed connective tissue disease (MCTD). Systemic sclerosis and undifferentiated connective tissue disease will not be touched as these diseases are developed in specific chapters of this book.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. Epub 1997/10/27.

    CAS  PubMed  Google Scholar 

  2. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86. Epub 2012/05/04, Copyright © 2012 by the American College of Rheumatology [Reprint].

    PubMed Central  PubMed  Google Scholar 

  3. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center II Predictor variables for mortality. J Rheumatol. 1995;22(7):1265–70. Epub 1995/07/01.

    CAS  PubMed  Google Scholar 

  4. Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol. 1996;35(3):248–54. Epub 1996/03/01.

    CAS  PubMed  Google Scholar 

  5. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1999;78(3):167–75. Epub 1999/06/03.

    CAS  Google Scholar 

  6. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82(5):299–308. Epub 2003/10/08.

    Google Scholar 

  7. Matthay RA, Schwarz MI, Petty TL, Stanford RE, Gupta RC, Sahn SA, et al. Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore). 1975;54(5):397–409. Epub 1975/09/01.

    CAS  Google Scholar 

  8. Haupt HM, Moore GW, Hutchins GM. The lung in systemic lupus erythematosus. Analysis of the pathologic changes in 120 patients. Am J Med. 1981;71(5):791–8.

    CAS  PubMed  Google Scholar 

  9. Colby TV. Pulmonary pathology in patients with systemic autoimmune diseases. Clin Chest Med. 1998;19(4):587–612, vii. Epub 1999/01/26.

    CAS  PubMed  Google Scholar 

  10. Abramson SB, Dobro J, Eberle MA, Benton M, Reibman J, Epstein H, et al. Acute reversible hypoxemia in systemic lupus erythematosus. Ann Intern Med. 1991;114(11):941–7. Epub 1991/06/01.

    CAS  PubMed  Google Scholar 

  11. Martinez-Taboada VM, Blanco R, Armona J, Fernandez-Sueiro JL, Rodriguez-Valverde V. Acute reversible hypoxemia in systemic lupus erythematosus: a new syndrome or an index of disease activity? Lupus. 1995;4(4):259–62. Epub 1995/08/01.

    CAS  PubMed  Google Scholar 

  12. Susanto I, Peters JI. Acute lupus pneumonitis with normal chest radiograph. Chest. 1997;111(6):1781–3. Epub 1997/06/01.

    CAS  PubMed  Google Scholar 

  13. Murin S, Wiedemann HP, Matthay RA. Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med. 1998;19(4):641–65, viii. Epub 1999/01/26.

    CAS  PubMed  Google Scholar 

  14. Raj R, Murin S, Matthay RA, Wiedemann HP. Systemic lupus erythematosus in the intensive care unit. Crit Care Clin. 2002;18(4):781–803. Epub 2002/11/07.

    PubMed  Google Scholar 

  15. Aringer M, Smolen JS. Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus. 2004;13(5):344–7. Epub 2004/07/03.

    CAS  PubMed  Google Scholar 

  16. Zamora MR, Warner ML, Tuder R, Schwarz MI. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore). 1997;76(3):192–202. Epub 1997/05/01.

    CAS  Google Scholar 

  17. Liu MF, Lee JH, Weng TH, Lee YY. Clinical experience of 13 cases with severe pulmonary hemorrhage in systemic lupus erythematosus with active nephritis. Scand J Rheumatol. 1998;27(4):291–5. Epub 1998/09/29.

    CAS  PubMed  Google Scholar 

  18. Schwab EP, Schumacher Jr HR, Freundlich B, Callegari PE. Pulmonary alveolar hemorrhage in systemic lupus erythematosus. Semin Arthritis Rheum. 1993;23(1):8–15. Epub 1993/08/01.

    CAS  PubMed  Google Scholar 

  19. Santos-Ocampo AS, Mandell BF, Fessler BJ. Alveolar hemorrhage in systemic lupus erythematosus: presentation and management. Chest. 2000;118(4):1083–90. Epub 2000/10/18.

    CAS  PubMed  Google Scholar 

  20. Myers JL, Katzenstein AA. Microangiitis in lupus-induced pulmonary hemorrhage. Am J Clin Pathol. 1986;85(5):552–6. Epub 1986/05/01.

    CAS  PubMed  Google Scholar 

  21. Quadrelli SA, Alvarez C, Arce SC, Paz L, Sarano J, Sobrino EM, et al. Pulmonary involvement of systemic lupus erythematosus: analysis of 90 necropsies. Lupus. 2009;18(12):1053–60. Epub 2009/09/19.

    CAS  PubMed  Google Scholar 

  22. Falk RJ, Hogan S, Carey TS, Jennette JC. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. Ann Intern Med. 1990;113(9):656–63. Epub 1990/11/01.

    CAS  PubMed  Google Scholar 

  23. Crausman RS, Achenbach GA, Pluss WT, O'Brien RF, Jennings CA. Pulmonary capillaritis and alveolar hemorrhage associated with the antiphospholipid antibody syndrome. J Rheumatol. 1995;22(3):554–6. Epub 1995/03/01.

    CAS  PubMed  Google Scholar 

  24. Schwarz MI, Sutarik JM, Nick JA, Leff JA, Emlen JW, Tuder RM. Pulmonary capillaritis and diffuse alveolar hemorrhage. A primary manifestation of polymyositis. Am J Respir Crit Care Med. 1995;151:2037–40.

    CAS  PubMed  Google Scholar 

  25. Hughson MD, He Z, Henegar J, McMurray R. Alveolar hemorrhage and renal microangiopathy in systemic lupus erythematosus. Arch Pathol Lab Med. 2001;125(4):475–83. Epub 2001/03/22.

    CAS  PubMed  Google Scholar 

  26. Badsha H, Teh CL, Kong KO, Lian TY, Chng HH. Pulmonary hemorrhage in systemic lupus erythematosus. Semin Arthritis Rheum. 2004;33(6):414–21. Epub 2004/06/11.

    PubMed  Google Scholar 

  27. Ewan PW, Jones HA, Rhodes CG, Hughes JM. Detection of intrapulmonary hemorrhage with carbon monoxide uptake. Application in goodpasture’s syndrome. N Engl J Med. 1976;295(25):1391–6. Epub 1976/12/16.

    CAS  PubMed  Google Scholar 

  28. Erickson RW, Franklin WA, Emlen W. Treatment of hemorrhagic lupus pneumonitis with plasmapheresis. Semin Arthritis Rheum. 1994;24(2):114–23. Epub 1994/10/01.

    CAS  PubMed  Google Scholar 

  29. Euler HH, Schroeder JO, Harten P, Zeuner RA, Gutschmidt HJ. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum. 1994;37(12):1784–94. Epub 1994/12/01.

    CAS  PubMed  Google Scholar 

  30. Keane MP, Lynch 3rd JP. Pleuropulmonary manifestations of systemic lupus erythematosus. Thorax. 2000;55(2):159–66. Epub 2000/01/20.

    CAS  PubMed Central  PubMed  Google Scholar 

  31. Rojas-Serrano J, Pedroza J, Regalado J, Robledo J, Reyes E, Sifuentes-Osornio J, et al. High prevalence of infections in patients with systemic lupus erythematosus and pulmonary haemorrhage. Lupus. 2008;17(4):295–9. Epub 2008/04/17.

    CAS  PubMed  Google Scholar 

  32. Specks U. Diffuse alveolar hemorrhage syndromes. Curr Opin Rheumatol. 2001;13(1):12–7. Epub 2001/01/10.

    CAS  PubMed  Google Scholar 

  33. Martinez-Martinez MU, Abud-Mendoza C. Predictors of mortality in diffuse alveolar haemorrhage associated with systemic lupus erythematosus. Lupus. 2011;20(6):568–74. Epub 2011/05/12.

    CAS  PubMed  Google Scholar 

  34. Kim WU, Kim SI, Yoo WH, Park JH, Min JK, Kim SC, et al. Adult respiratory distress syndrome in systemic lupus erythematosus: causes and prognostic factors: a single center, retrospective study. Lupus. 1999;8(7):552–7. Epub 1999/09/14.

    CAS  PubMed  Google Scholar 

  35. Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12(7):530–4. Epub 2003/08/02.

    CAS  PubMed  Google Scholar 

  36. Cervera R, Bucciarelli S, Plasin MA, Gomez-Puerta JA, Plaza J, Pons-Estel G, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry”. J Autoimmun. 2009;32(3–4):240–5. Epub 2009/03/28.

    CAS  PubMed  Google Scholar 

  37. Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gomez-Puerta JA, Ramos-Casals M, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006;54(8):2568–76. Epub 2006/07/27.

    PubMed  Google Scholar 

  38. Costedoat-Chalumeau N, Arnaud L, Saadoun D, Chastre J, Leroux G, Cacoub P, et al. [Catastrophic antiphospholipid syndrome]. La Revue de medecine interne/fondee par la Societe nationale francaise de medecine interne. 2012;33(4):194––9. Epub 2012/02/22. Le syndrome catastrophique des antiphospholipides.

    PubMed  Google Scholar 

  39. Weinrib L, Sharma OP, Quismorio Jr FP. A long-term study of interstitial lung disease in systemic lupus erythematosus. Semin Arthritis Rheum. 1990;20(1):48–56. Epub 1990/08/01.

    CAS  PubMed  Google Scholar 

  40. Fenlon HM, Doran M, Sant SM, Breatnach E. High-resolution chest CT in systemic lupus erythematosus. AJR Am J Roentgenol. 1996;166(2):301–7. Epub 1996/02/01.

    CAS  PubMed  Google Scholar 

  41. Boulware DW, Hedgpeth MT. Lupus pneumonitis and anti-SSA(Ro) antibodies. J Rheumatol. 1989;16(4):479–81. Epub 1989/04/01.

    CAS  PubMed  Google Scholar 

  42. Groen H, ter Borg EJ, Postma DS, Wouda AA, van der Mark TW, Kallenberg CG. Pulmonary function in systemic lupus erythematosus is related to distinct clinical, serologic, and nailfold capillary patterns. Am J Med. 1992;93(6):619–27. Epub 1992/12/01.

    CAS  PubMed  Google Scholar 

  43. Eisenberg H, Dubois EL, Sherwin RP, Balchum OJ. Diffuse interstitial lung disease in systemic lupus erythematosus. Ann Intern Med. 1973;79(1):37–45. Epub 1973/07/01.

    CAS  PubMed  Google Scholar 

  44. Esmaeilbeigi F, Juvet S, Hwang D, Mittoo S. Desquamative interstitial pneumonitis in a patient with systemic lupus erythematosus. Can Respir J. 2012;19(1):50–2. Epub 2012/02/15.

    PubMed Central  PubMed  Google Scholar 

  45. Fink SD, Kremer JM. Successful treatment of interstitial lung disease in systemic lupus erythematosus with methotrexate. J Rheumatol. 1995;22(5):967–9. Epub 1995/05/01.

    CAS  PubMed  Google Scholar 

  46. Yum HK, Kim ES, Ok KS, Lee HK, Choi SJ. Lymphocytic interstitial pneumonitis associated with Epstein-Barr virus in Systemic Lupus Erythematosus and Sjogren’s Syndrome. Complete remission with corticosteriod and cyclophosphamide. Korean J Intern Med. 2002;17(3):198–203. Epub 2002/09/27.

    PubMed  Google Scholar 

  47. Filipek MS, Thompson ME, Wang PL, Gosselin MV, L Primack S. Lymphocytic interstitial pneumonitis in a patient with systemic lupus erythematosus: radiographic and high-resolution CT findings. J Thorac Imaging. 2004;19(3):200–3. Epub 2004/07/27.

    PubMed  Google Scholar 

  48. Min JK, Hong YS, Park SH, Park JH, Lee SH, Lee YS, et al. Bronchiolitis obliterans organizing pneumonia as an initial manifestation in patients with systemic lupus erythematosus. J Rheumatol. 1997;24(11):2254–7. Epub 1998/02/07.

    CAS  PubMed  Google Scholar 

  49. Begum S, Li C, Wedderburn LR, Blackwell V, Isenberg DA. Concurrence of sarcoidosis and systemic lupus erythematosus in three patients. Clin Exp Rheumatol. 2002;20(4):549–52. Epub 2002/08/15.

    CAS  PubMed  Google Scholar 

  50. Warrington KJ, Moder KG, Brutinel WM. The shrinking lungs syndrome in systemic lupus erythematosus. Mayo Clin Proc. 2000;75(5):467–72.

    CAS  PubMed  Google Scholar 

  51. Toya SP, Tzelepis GE. Association of the shrinking lung syndrome in systemic lupus erythematosus with pleurisy: a systematic review. Semin Arthritis Rheum. 2009;39(1):30–7. Epub 2008/07/01.

    PubMed  Google Scholar 

  52. Wilcox PG, Stein HB, Clarke SD, Pare PD, Pardy RL. Phrenic nerve function in patients with diaphragmatic weakness and systemic lupus erythematosus. Chest. 1988;93(2):352–8. Epub 1988/02/01.

    CAS  PubMed  Google Scholar 

  53. Laroche CM, Mulvey DA, Hawkins PN, Walport MJ, Strickland B, Moxham J, et al. Diaphragm strength in the shrinking lung syndrome of systemic lupus erythematosus. Q J Med. 1989;71(265):429–39. Epub 1989/05/01.

    CAS  PubMed  Google Scholar 

  54. Hardy K, Herry I, Attali V, Cadranel J, Similowski T. Bilateral phrenic paralysis in a patient with systemic lupus erythematosus. Chest. 2001;119(4):1274–7. Epub 2001/04/11.

    CAS  PubMed  Google Scholar 

  55. Hawkins P, Davison AG, Dasgupta B, Moxham J. Diaphragm strength in acute systemic lupus erythematosus in a patient with paradoxical abdominal motion and reduced lung volumes. Thorax. 2001;56(4):329–30. Epub 2001/03/20.

    CAS  PubMed Central  PubMed  Google Scholar 

  56. Perez-de-Llano LA, Castro-Anon O, Lopez MJ, Escalona E, Teijeira S, Sanchez-Andrade A. Shrinking lung syndrome caused by lupus myopathy. QJM. 2011;104(3):259–62. Epub 2010/10/12.

    CAS  PubMed  Google Scholar 

  57. Oud KT, Bresser P, ten Berge RJ, Jonkers RE. The shrinking lung syndrome in systemic lupus erythematosus: improvement with corticosteroid therapy. Lupus. 2005;14(12):959–63. Epub 2006/01/24.

    CAS  PubMed  Google Scholar 

  58. Karim MY, Miranda LC, Tench CM, Gordon PA, D'Cruz DP, Khamashta MA, et al. Presentation and prognosis of the shrinking lung syndrome in systemic lupus erythematosus. Semin Arthritis Rheum. 2002;31(5):289–98. Epub 2002/04/20.

    PubMed  Google Scholar 

  59. Langenskiold E, Bonetti A, Fitting JW, Heinzer R, Dudler J, Spertini F, et al. Shrinking lung syndrome successfully treated with rituximab and cyclophosphamide. Respiration. 2012;84(2):144–9. Epub 2012/02/04.

    PubMed  Google Scholar 

  60. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham 3rd CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–8. Epub 2010/08/12.

    PubMed  Google Scholar 

  61. Mattey DL, Dawes PT, Clarke S, Fisher J, Brownfield A, Thomson W, et al. Relationship among the HLA-DRB1 shared epitope, smoking, and rheumatoid factor production in rheumatoid arthritis. Arthritis Rheum. 2002;47(4):403–7. Epub 2002/09/05.

    CAS  PubMed  Google Scholar 

  62. Costenbader KH, Feskanich D, Mandl LA, Karlson EW. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med. 2006;119((6):503 e1–9. Epub 2006/06/06.

    Google Scholar 

  63. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38–46. Epub 2005/12/31.

    CAS  PubMed  Google Scholar 

  64. Lee HS, Irigoyen P, Kern M, Lee A, Batliwalla F, Khalili H, et al. Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide: a mixed picture in three large North American rheumatoid arthritis cohorts. Arthritis Rheum. 2007;56(6):1745–53. Epub 2007/05/29.

    CAS  PubMed  Google Scholar 

  65. Klareskog L, Ronnelid J, Lundberg K, Padyukov L, Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol. 2008;26:651–75. Epub 2008/01/05.

    CAS  PubMed  Google Scholar 

  66. Gizinski AM, Mascolo M, Loucks JL, Kervitsky A, Meehan RT, Brown KK, et al. Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol. 2009;28(5):611–3. Epub 2009/03/03.

    PubMed Central  PubMed  Google Scholar 

  67. Lee DM, Phillips R, Hagan EM, Chibnik LB, Costenbader KH, Schur PH. Quantifying anti-cyclic citrullinated peptide titres: clinical utility and association with tobacco exposure in patients with rheumatoid arthritis. Ann Rheum Dis. 2009;68(2):201–8. Epub 2008/04/09.

    CAS  PubMed  Google Scholar 

  68. Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583–91. Epub 2010/02/16.

    PubMed Central  PubMed  Google Scholar 

  69. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003;62(8):722–7. Epub 2003/07/16.

    CAS  PubMed Central  PubMed  Google Scholar 

  70. Olson AL, Swigris JJ, Sprunger DB, Fischer A, Fernandez-Perez ER, Solomon J, et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med. 2011;183(3):372–8. Epub 2010/09/21.

    PubMed  Google Scholar 

  71. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax. 2001;56(8):622–7. Epub 2001/07/20.

    CAS  PubMed Central  PubMed  Google Scholar 

  72. Lamblin C, Bergoin C, Saelens T, Wallaert B. Interstitial lung diseases in collagen vascular diseases. Eur Respir J Suppl. 2001;32:69s–80. Epub 2002/01/31.

    CAS  PubMed  Google Scholar 

  73. Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton S, et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford). 2007;46(2):350–7.

    CAS  Google Scholar 

  74. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis. 2002;61(6):517–21. Epub 2002/05/15.

    CAS  PubMed Central  PubMed  Google Scholar 

  75. Gochuico BR, Avila NA, Chow CK, Novero LJ, Wu HP, Ren P, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168(2):159–66. Epub 2008/01/30.

    CAS  PubMed  Google Scholar 

  76. Wilsher M, Voight L, Milne D, Teh M, Good N, Kolbe J, et al. Prevalence of airway and parenchymal abnormalities in newly diagnosed rheumatoid arthritis. Respir Med. 2012;106(10):1441–6. Epub 2012/07/17.

    PubMed  Google Scholar 

  77. Dixon WG, Hyrich KL, Watson KD, Lunt M, Symmons DP. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2010;69(6):1086–91. Epub 2010/05/07.

    CAS  PubMed Central  PubMed  Google Scholar 

  78. Rangel-Moreno J, Hartson L, Navarro C, Gaxiola M, Selman M, Randall TD. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest. 2006;116(12):3183–94. Epub 2006/12/05.

    CAS  PubMed Central  PubMed  Google Scholar 

  79. Kim DS. Interstitial lung disease in rheumatoid arthritis: recent advances. Curr Opin Pulm Med. 2006;12(5):346–53. Epub 2006/08/24.

    PubMed  Google Scholar 

  80. Flaherty KR, Colby TV, Travis WD, Toews GB, Mumford J, Murray S, et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med. 2003;167(10):1410–5. Epub 2003/03/05.

    PubMed  Google Scholar 

  81. Song JW, Do KH, Kim MY, Jang SJ, Colby TV, Kim DS. Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest. 2009;136(1):23–30. Epub 2009/03/04.

    PubMed  Google Scholar 

  82. Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007;175(7):705–11. Epub 2007/01/16.

    PubMed  Google Scholar 

  83. Tanaka N, Kim JS, Newell JD, Brown KK, Cool CD, Meehan R, et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology. 2004;232(1):81–91. Epub 2004/05/29.

    PubMed  Google Scholar 

  84. Hakala M. Poor prognosis in patients with rheumatoid arthritis hospitalized for interstitial lung fibrosis. Chest. 1988;93(1):114–8. Epub 1988/01/01.

    CAS  PubMed  Google Scholar 

  85. Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Van Uden JH, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35(6):1322–8. Epub 2009/12/10.

    CAS  PubMed  Google Scholar 

  86. Tsuchiya Y, Takayanagi N, Sugiura H, Miyahara Y, Tokunaga D, Kawabata Y, et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J. 2011;37(6):1411–7. Epub 2010/10/05.

    CAS  PubMed  Google Scholar 

  87. Cottin V. Pragmatic prognostic approach of rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35(6):1206–8. Epub 2010/06/02.

    CAS  PubMed  Google Scholar 

  88. Hamblin MJ, Horton MR. Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemma. Pulm Med. 2011;2011:872120. Epub 2011/06/11.

    PubMed Central  PubMed  Google Scholar 

  89. Mohr M, Jacobi AM. Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade. Scand J Rheumatol. 2011;40(5):400–1. Epub 2011/10/04.

    CAS  PubMed  Google Scholar 

  90. Suda T, Kaida Y, Nakamura Y, Enomoto N, Fujisawa T, Imokawa S, et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med. 2009;103(6):846–53. Epub 2009/02/03.

    PubMed  Google Scholar 

  91. Park IN, Kim DS, Shim TS, Lim CM, Lee SD, Koh Y, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest. 2007;132(1):214–20. Epub 2007/04/03.

    PubMed  Google Scholar 

  92. Nyhall-Wahlin BM, Jacobsson LT, Petersson IF, Turesson C. Smoking is a strong risk factor for rheumatoid nodules in early rheumatoid arthritis. Ann Rheum Dis. 2006;65(5):601–6. Epub 2005/09/17.

    PubMed Central  PubMed  Google Scholar 

  93. Kerstens PJ, Boerbooms AM, Jeurissen ME, Fast JH, Assmann KJ, van de Putte LB. Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis. An analysis of ten cases. J Rheumatol. 1992;19(6):867–71. Epub 1992/06/01.

    CAS  PubMed  Google Scholar 

  94. Braun MG, Van Rhee R, Becker-Capeller D. [Development and/or increase of rheumatoid nodules in RA patients following leflunomide therapy]. Z Rheumatol. 2004;63(1):84–7. Epub 2004/03/03. Neuauftreten und/oder Zunahme von Rheumaknoten unter Leflunomidtherapie bei RA-Patienten.

    CAS  PubMed  Google Scholar 

  95. van Ede A, den Broeder A, Wagenaar M, van Riel P, Creemers MC. Etanercept-related extensive pulmonary nodulosis in a patient with rheumatoid arthritis. J Rheumatol. 2007;34(7):1590–2. Epub 2007/07/05.

    PubMed  Google Scholar 

  96. Winne L, Praet M, Brusselle G, Veys E, Mielants H. Bilateral spontaneous pneumothorax in a patient with pulmonary rheumatoid nodules, secondary infected by Aspergillus. Clin Rheumatol. 2007;26(7):1180–2. Epub 2006/05/04.

    PubMed  Google Scholar 

  97. Bakheet SM, Powe J. Fluorine-18-fluorodeoxyglucose uptake in rheumatoid arthritis-associated lung disease in a patient with thyroid cancer. J Nucl Med. 1998;39(2):234–6. Epub 1998/02/26.

    CAS  PubMed  Google Scholar 

  98. Schreiber J, Koschel D, Kekow J, Waldburg N, Goette A, Merget R. Rheumatoid pneumoconiosis (Caplan’s syndrome). Eur J Intern Med. 2010;21(3):168–72. Epub 2010/05/25.

    CAS  PubMed  Google Scholar 

  99. Cottin V, Nunes H, Mouthon L, Gamondes D, Lazor R, Hachulla E, et al. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum. 2011;63(1):295–304. Epub 2010/10/12.

    PubMed  Google Scholar 

  100. Calatayud J, Candelas G, Gomez A, Morado C, Trancho FH. Nodular pulmonary amyloidosis in a patient with rheumatoid arthritis. Clin Rheumatol. 2007;26(10):1797–8. Epub 2007/03/03.

    CAS  PubMed  Google Scholar 

  101. Yue CC, Park CH, Kushner I. Apical fibrocavitary lesions of the lung in rheumatoid arthritis. Report of two cases and review of the literature. Am J Med. 1986;81(4):741–6. Epub 1986/10/01.

    CAS  PubMed  Google Scholar 

  102. Naschitz JE, Yeshurun D, Scharf Y, Sajrawi I, Lazarov NB, Boss JH. Recurrent massive alveolar hemorrhage, crescentic glomerulonephritis, and necrotizing vasculitis in a patient with rheumatoid arthritis. Arch Intern Med. 1989;149(2):406–8. Epub 1989/02/01.

    CAS  PubMed  Google Scholar 

  103. Torralbo A, Herrero JA, Portoles J, Barrientos A. Alveolar hemorrhage associated with antineutrophil cytoplasmic antibodies in rheumatoid arthritis. Chest. 1994;105(5):1590–2. Epub 1994/05/01.

    CAS  PubMed  Google Scholar 

  104. Chikura B, Lane S, Dawson JK. Clinical expression of leflunomide-induced pneumonitis. Rheumatology (Oxford). 2009;48(9):1065–8. Epub 2009/03/27.

    CAS  Google Scholar 

  105. Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M, Xaubet A, Bosch X. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med. 2011;124(5):386–94. Epub 2011/05/03.

    CAS  PubMed  Google Scholar 

  106. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011;41(2):256–64. Epub 2011/02/01.

    CAS  PubMed  Google Scholar 

  107. Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ostor AJ. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford). 2012;51(4):653–62. Epub 2011/12/14.

    CAS  Google Scholar 

  108. Camus P, Bonniaud P, Fanton A, Camus C, Baudaun N, Foucher P. Drug-induced and iatrogenic infiltrative lung disease. Clin Chest Med. 2004;25(3):479–519. vi. Epub 2004/08/28.

    PubMed  Google Scholar 

  109. Furukawa H, Oka S, Shimada K, Tsuchiya N, Tohma S. HLA-A*31:01 and methotrexate-induced interstitial lung disease in Japanese rheumatoid arthritis patients: a multidrug hypersensitivity marker? Ann Rheum Dis. 2013;72(1):153–5. Epub 2012/08/14.

    CAS  PubMed  Google Scholar 

  110. Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum. 2006;54(5):1435–9. Epub 2006/04/29.

    CAS  PubMed  Google Scholar 

  111. Sawada T, Inokuma S, Sato T, Otsuka T, Saeki Y, Takeuchi T, et al. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48(9):1069–72. Epub 2009/03/27.

    CAS  Google Scholar 

  112. Alarcon GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case–control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997;127(5):356–64.

    CAS  PubMed  Google Scholar 

  113. Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest. 2013;143(3):814–24. Epub 2013/03/06.

    CAS  PubMed Central  PubMed  Google Scholar 

  114. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762–84. Epub 2008/06/03.

    CAS  PubMed  Google Scholar 

  115. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5):625–39. Epub 2012/04/05.

    CAS  Google Scholar 

  116. Hadjinicolaou AV, Nisar MK, Bhagat S, Parfrey H, Chilvers ER, Ostor AJ. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases – a systematic literature review. Rheumatology (Oxford). 2011;50(12):2297–305. Epub 2011/10/25.

    Google Scholar 

  117. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8. Epub 2002/05/15.

    CAS  PubMed Central  PubMed  Google Scholar 

  118. Boitiaux JF, Debray MP, Nicaise-Roland P, Adle-Biassette H, Danel C, Clerici C, et al. Idiopathic interstitial lung disease with anti-SSA antibody. Rheumatology (Oxford). 2011;50(12):2245–50. Epub 2011/10/11.

    CAS  Google Scholar 

  119. Franquet T, Gimenez A, Monill JM, Diaz C, Geli C. Primary Sjogren's syndrome and associated lung disease: CT findings in 50 patients. AJR Am J Roentgenol. 1997;169(3):655–8. Epub 1997/09/01.

    CAS  PubMed  Google Scholar 

  120. Uffmann M, Kiener HP, Bankier AA, Baldt MM, Zontsich T, Herold CJ. Lung manifestation in asymptomatic patients with primary Sjogren syndrome: assessment with high resolution CT and pulmonary function tests. J Thorac Imaging. 2001;16(4):282–9. Epub 2001/10/31.

    CAS  PubMed  Google Scholar 

  121. Koyama M, Johkoh T, Honda O, Mihara N, Kozuka T, Tomiyama N, et al. Pulmonary involvement in primary Sjogren’s syndrome: spectrum of pulmonary abnormalities and computed tomography findings in 60 patients. J Thorac Imaging. 2001;16(4):290–6. Epub 2001/10/31.

    CAS  PubMed  Google Scholar 

  122. Taouli B, Brauner MW, Mourey I, Lemouchi D, Grenier PA. Thin-section chest CT findings of primary Sjogren’s syndrome: correlation with pulmonary function. Eur Radiol. 2002;12(6):1504–11. Epub 2002/06/04.

    PubMed  Google Scholar 

  123. Lohrmann C, Uhl M, Warnatz K, Ghanem N, Kotter E, Schaefer O, et al. High-resolution CT imaging of the lung for patients with primary Sjogren’s syndrome. Eur J Radiol. 2004;52(2):137–43. Epub 2004/10/19.

    PubMed  Google Scholar 

  124. Constantopoulos SH, Papadimitriou CS, Moutsopoulos HM. Respiratory manifestations in primary Sjogren’s syndrome. A clinical, functional, and histologic study. Chest. 1985;88(2):226–9.

    CAS  PubMed  Google Scholar 

  125. Davidson BK, Kelly CA, Griffiths ID. Ten year follow up of pulmonary function in patients with primary Sjogren's syndrome. Ann Rheum Dis. 2000;59(9):709–12. Epub 2000/09/08.

    CAS  PubMed Central  PubMed  Google Scholar 

  126. Palm O, Garen T, Berge Enger T, Jensen JL, Lund MB, Aalokken TM, et al. Clinical pulmonary involvement in primary Sjogren’s syndrome: prevalence, quality of life and mortality–a retrospective study based on registry data. Rheumatology (Oxford). 2013;52(1):173–9. Epub 2012/11/30.

    Google Scholar 

  127. Hatron PY, Wallaert B, Gosset D, Tonnel AB, Gosselin B, Voisin C, et al. Subclinical lung inflammation in primary Sjogren’s syndrome. Arthritis Rheum. 1987;30(11):1226–31. Epub 1987/11/01.

    CAS  PubMed  Google Scholar 

  128. Wallaert B, Prin L, Hatron PY, Ramon P, Tonnel AB, Voisin C. Lymphocyte subpopulations in bronchoalveolar lavage in Sjogren’s syndrome. Evidence for an expansion of cytotoxic/suppressor subset in patients with alveolar neutrophilia. Chest. 1987;92(6):1025–31. Epub 1987/12/01.

    CAS  PubMed  Google Scholar 

  129. Deheinzelin D, Capelozzi VL, Kairalla RA, Barbas Filho JV, Saldiva PH, de Carvalho CR. Interstitial lung disease in primary Sjogren’s syndrome. Clinical-pathological evaluation and response to treatment. Am J Respir Crit Care Med. 1996;154(3 Pt 1):794–9. Epub 1996/09/01.

    CAS  PubMed  Google Scholar 

  130. Yamadori I, Fujita J, Bandoh S, Tokuda M, Tanimoto Y, Kataoka M, et al. Nonspecific interstitial pneumonia as pulmonary involvement of primary Sjogren’s syndrome. Rheumatol Int. 2002;22(3):89–92. Epub 2002/07/12.

    CAS  PubMed  Google Scholar 

  131. Tansey D, Wells AU, Colby TV, Ip S, Nikolakoupolou A, du Bois RM, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology. 2004;44(6):585–96.

    CAS  PubMed  Google Scholar 

  132. Usui Y, Kimula Y, Miura H, Kodaira Y, Takayama S, Nakayama M, et al. A case of bronchiolitis obliterans organizing pneumonia associated with primary Sjogren’s syndrome who died of superimposed diffuse alveolar damage. Respiration. 1992;59(2):122–4. Epub 1992/01/01.

    CAS  PubMed  Google Scholar 

  133. Farnam J, Jorizzo JL, Grant JA, Lavastida MT, Ichikawa Y, Daniels JC. Sjogren’s syndrome presenting with hypereosinophilia, lymphopenia and circulating immune complexes. Clin Exp Rheumatol. 1984;2(1):41–6. Epub 1984/01/01.

    CAS  PubMed  Google Scholar 

  134. Parambil JG, Myers JL, Ryu JH. Diffuse alveolar damage: uncommon manifestation of pulmonary involvement in patients with connective tissue diseases. Chest. 2006;130(2):553–8. Epub 2006/08/11.

    PubMed  Google Scholar 

  135. Johnston SL, Dudley CR, Unsworth DJ, Lock RJ. Life-threatening acute pulmonary haemorrhage in primary Sjogren’s syndrome with cryoglobulinaemia. Scand J Rheumatol. 2005;34(5):404–7. Epub 2005/10/20.

    CAS  PubMed  Google Scholar 

  136. Linstow M, Kriegbaum NJ, Backer V, Ulrik C, Oxholm P. A follow-up study of pulmonary function in patients with primary Sjogren’s syndrome. Rheumatol Int. 1990;10(2):47–9. Epub 1990/01/01.

    CAS  PubMed  Google Scholar 

  137. Ito I, Nagai S, Kitaichi M, Nicholson AG, Johkoh T, Noma S, et al. Pulmonary manifestations of primary Sjogren’s syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med. 2005;171(6):632–8. Epub 2004/12/08.

    PubMed  Google Scholar 

  138. Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH. Interstitial lung disease in primary Sjogren syndrome. Chest. 2006;130(5):1489–95. Epub 2006/11/14.

    PubMed  Google Scholar 

  139. Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet. 2012;380(9842):689–98. Epub 2012/08/21.

    PubMed  Google Scholar 

  140. Fox RI. Sjogren’s syndrome: evolving therapies. Expert Opin Investig Drugs. 2003;12(2):247–54. Epub 2003/01/31.

    CAS  PubMed  Google Scholar 

  141. Gottenberg JE, Cinquetti G, Larroche C, Combe B, Hachulla E, Meyer O, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren’s syndrome: results in 78 patients of the Auto Immune and Rituximab registry. Ann Rheum Dis. 2013;72(6):1026–31.

    CAS  PubMed  Google Scholar 

  142. Nicholson AG, Wotherspoon AC, Diss TC, Hansell DM, Du Bois R, Sheppard MN, et al. Reactive pulmonary lymphoid disorders. Histopathology. 1995;26(5):405–12. Epub 1995/05/01.

    CAS  PubMed  Google Scholar 

  143. Johkoh T, Muller NL, Pickford HA, Hartman TE, Ichikado K, Akira M, et al. Lymphocytic interstitial pneumonia: thin-section CT findings in 22 patients. Radiology. 1999;212(2):567–72. Epub 1999/08/03.

    CAS  PubMed  Google Scholar 

  144. Cha SI, Fessler MB, Cool CD, Schwarz MI, Brown KK. Lymphoid interstitial pneumonia: clinical features, associations and prognosis. Eur Respir J. 2006;28(2):364–9. Epub 2006/03/31.

    PubMed  Google Scholar 

  145. Johkoh T, Ichikado K, Akira M, Honda O, Tomiyama N, Mihara N, et al. Lymphocytic interstitial pneumonia: follow-up CT findings in 14 patients. J Thorac Imaging. 2000;15(3):162–7. Epub 2000/08/06.

    CAS  PubMed  Google Scholar 

  146. Jagirdar J, Chikkamuniyappa S, Sirohi D, McCarthy MJ, Peters JI. Cystic lung lesions in Sjogren syndrome: analysis of lymphocyte subsets in tissue with clinico-radiologic-pathologic correlation. Ann Diagn Pathol. 2013;17(1):113–6. Epub 2012/06/05.

    PubMed  Google Scholar 

  147. Ichikawa Y, Kinoshita M, Koga T, Oizumi K, Fujimoto K, Hayabuchi N. Lung cyst formation in lymphocytic interstitial pneumonia: CT features. J Comput Assist Tomogr. 1994;18(5):745–8. Epub 1994/09/01.

    CAS  PubMed  Google Scholar 

  148. Foguem C, Launay D, Lambert M, Quemeneur T, Hachulla E, Wallaert B, et al. Cystic lung disease associated with Sjogren’s syndrome: 2 cases. La Revue de medecine interne / fondee par la Societe nationale francaise de medecine interne. 2006;27(8):620–4. Epub 2006/08/01. Maladie kystique pulmonaire compliquant le syndrome de Gougerot-Sjogren: deux observations.

    CAS  PubMed  Google Scholar 

  149. Jeong YJ, Lee KS, Chung MP, Han J, Chung MJ, Kim KI, et al. Amyloidosis and lymphoproliferative disease in Sjogren syndrome: thin-section computed tomography findings and histopathologic comparisons. J Comput Assist Tomogr. 2004;28(6):776–81. Epub 2004/11/13.

    PubMed  Google Scholar 

  150. Ekstrom Smedby K, Vajdic CM, Falster M, Engels EA, Martinez-Maza O, Turner J, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111(8):4029–38. Epub 2008/02/12.

    PubMed Central  PubMed  Google Scholar 

  151. Dias C, Isenberg DA. Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. Nat Rev Rheumatol. 2011;7(6):360–8. Epub 2011/06/04.

    CAS  PubMed  Google Scholar 

  152. Royer B, Cazals-Hatem D, Sibilia J, Agbalika F, Cayuela JM, Soussi T, et al. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood. 1997;90(2):766–75. Epub 1997/07/15.

    CAS  PubMed  Google Scholar 

  153. Cordier JF, Chailleux E, Lauque D, Reynaud-Gaubert M, Dietemann-Molard A, Dalphin JC, et al. Primary pulmonary lymphomas. A clinical study of 70 cases in nonimmunocompromised patients. Chest. 1993;103(1):201–8.

    CAS  PubMed  Google Scholar 

  154. Papiris SA, Kalomenidis I, Malagari K, Kapotsis GE, Harhalakis N, Manali ED, et al. Extranodal marginal zone B-cell lymphoma of the lung in Sjogren’s syndrome patients: reappraisal of clinical, radiological, and pathology findings. Respir Med. 2007;101(1):84–92. Epub 2006/06/01.

    PubMed  Google Scholar 

  155. Borie R, Wislez M, Thabut G, Antoine M, Rabbat A, Couderc LJ, et al. Clinical characteristics and prognostic factors of pulmonary MALT lymphoma. Eur Respir J. 2009;34(6):1408–16. Epub 2009/06/23.

    CAS  PubMed  Google Scholar 

  156. Honda O, Johkoh T, Ichikado K, Tomiyama N, Maeda M, Mihara N, et al. Differential diagnosis of lymphocytic interstitial pneumonia and malignant lymphoma on high-resolution CT. AJR Am J Roentgenol. 1999;173(1):71–4. Epub 1999/07/09.

    CAS  PubMed  Google Scholar 

  157. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer. 2004;4(8):644–53. Epub 2004/08/03.

    CAS  PubMed  Google Scholar 

  158. Baqir M, Kluka EM, Aubry MC, Hartman TE, Yi ES, Bauer PR, et al. Amyloid-associated cystic lung disease in primary Sjogren's syndrome. Respir Med. 2013;107(4):616–21.

    PubMed  Google Scholar 

  159. Delevaux I, Andre M, Amoura Z, Kemeny JL, Piette JC, Aumaitre O. Concomitant diagnosis of primary Sjogren's syndrome and systemic AL amyloidosis. Ann Rheum Dis. 2001;60(7):694–5. Epub 2001/06/19.

    CAS  PubMed Central  PubMed  Google Scholar 

  160. Gal I, Kovacs J, Zeher M. Case series: coexistence of Sjogren's syndrome and sarcoidosis. J Rheumatol. 2000;27(10):2507–10. Epub 2000/10/19.

    CAS  PubMed  Google Scholar 

  161. Ramos-Casals M, Brito-Zeron P, Garcia-Carrasco M, Font J. Sarcoidosis or Sjogren syndrome? Clues to defining mimicry or coexistence in 59 cases. Medicine (Baltimore). 2004;83(2):85–95. Epub 2004/03/19.

    Google Scholar 

  162. Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61(11):980–5. Epub 2006/07/18.

    CAS  PubMed Central  PubMed  Google Scholar 

  163. Launay D, Hachulla E, Hatron PY, Jais X, Simonneau G, Humbert M. Pulmonary arterial hypertension: a rare complication of primary Sjogren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore). 2007;86(5):299–315. Epub 2007/09/18.

    Google Scholar 

  164. Saketkoo LA, Ascherman DP, Cottin V, Christopher-Stine L, Danoff SK, Oddis CV. Interstitial lung disease in idiopathic inflammatory myopathy. Curr Rheumatol Rev. 2010;6(2):108–19. Epub 2010/05/01.

    PubMed Central  PubMed  Google Scholar 

  165. Khan S, Christopher-Stine L. Polymyositis, dermatomyositis, and autoimmune necrotizing myopathy: clinical features. Rheum Dis Clin North Am. 2011;37(2):143–58, v. Epub 2011/03/30.

    PubMed  Google Scholar 

  166. Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest. 2009;136(5):1341–7. Epub 2009/07/08.

    PubMed  Google Scholar 

  167. Yang Y, Fujita J, Tokuda M, Bandoh S, Ishida T. Chronological evaluation of the onset of histologically confirmed interstitial pneumonia associated with polymyositis/dermatomyositis. Intern Med. 2002;41(12):1135–41. Epub 2003/01/11.

    PubMed  Google Scholar 

  168. Marie I, Josse S, Decaux O, Dominique S, Diot E, Landron C, et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev. 2012;11(10):739–45. Epub 2012/02/14.

    CAS  PubMed  Google Scholar 

  169. Owada T, Maezawa R, Kurasawa K, Okada H, Arai S, Fukuda T. Detection of inflammatory lesions by f-18 fluorodeoxyglucose positron emission tomography in patients with polymyositis and dermatomyositis. J Rheumatol. 2012;39(8):1659–65. Epub 2012/07/04.

    CAS  PubMed  Google Scholar 

  170. Del Grande F, Carrino JA, Del Grande M, Mammen AL, Christopher SL. Magnetic resonance imaging of inflammatory myopathies. Topics Magn Reson Imaging. 2011;22(2):39–43. Epub 2011/04/01.

    Google Scholar 

  171. Teixeira A, Cherin P, Demoule A, Levy-Soussan M, Straus C, Verin E, et al. Diaphragmatic dysfunction in patients with idiopathic inflammatory myopathies. Neuromusc Disord. 2005;15(1):32–9. Epub 2005/01/11.

    PubMed  Google Scholar 

  172. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357(9250):96–100. Epub 2001/02/24.

    CAS  PubMed  Google Scholar 

  173. Hervier B, Meyer A, Dieval C, Uzunhan Y, Devilliers H, Launay D, et al. Pulmonary hypertension in antisynthetase syndrome: prevalence, etiology and survival. Eur Respir J. 2013;42(5):1271–82.

    PubMed  Google Scholar 

  174. Tillie-Leblond I, Wislez M, Valeyre D, Crestani B, Rabbat A, Israel-Biet D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax. 2008;63(1):53–9. Epub 2007/06/15.

    CAS  PubMed  Google Scholar 

  175. Fernandez AB, Karas RH, Alsheikh-Ali AA, Thompson PD. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. Chest. 2008;134(4):824–30. Epub 2008/08/12.

    PubMed  Google Scholar 

  176. Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senecal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther. 2007;9(4):R78. Epub 2007/08/11.

    PubMed Central  PubMed  Google Scholar 

  177. Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest. 2010;138(6):1464–74. Epub 2010/12/09.

    PubMed  Google Scholar 

  178. Mammen AL. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol. 2011;7(6):343–54. Epub 2011/06/10.

    CAS  PubMed  Google Scholar 

  179. Katzap E, Barilla-LaBarca ML, Marder G. Antisynthetase syndrome. Curr Rheumatol Rep. 2011;13(3):175–81. Epub 2011/04/02.

    CAS  PubMed  Google Scholar 

  180. Hervier B, Devilliers H, Stanciu R, Meyer A, Uzunhan Y, Masseau A, et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev. 2012;12(2):210–7. Epub 2012/07/10.

    CAS  PubMed  Google Scholar 

  181. Lega JC, Cottin V, Fabien N, Thivolet-Bejui F, Cordier JF. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition? J Rheumatol. 2010;37(5):1000–9. Epub 2010/03/17.

    CAS  PubMed  Google Scholar 

  182. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore). 2005;84(4):231–49. Epub 2005/07/13.

    Google Scholar 

  183. Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49(9):1713–9. Epub 2010/05/26.

    CAS  Google Scholar 

  184. Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010;49(3):433–40. Epub 2009/12/18.

    CAS  Google Scholar 

  185. Hall JC, Casciola-Rosen L, Samedy LA, Werner J, Owoyemi K, Danoff SK, et al. Anti-MDA5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken). 2013;65(8):1307–15.

    CAS  Google Scholar 

  186. Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, Cadranel J, Delaval P, Ternamian PJ, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J. 2003;22(2):245–50. Epub 2003/09/04.

    CAS  PubMed  Google Scholar 

  187. Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med. 2001;164(7):1182–5. Epub 2001/10/24.

    CAS  PubMed  Google Scholar 

  188. Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004;63(3):297–301. Epub 2004/02/14.

    CAS  PubMed Central  PubMed  Google Scholar 

  189. Marie I, Hachulla E, Cherin P, Dominique S, Hatron PY, Hellot MF, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002;47(6):614–22. Epub 2003/01/11.

    CAS  PubMed  Google Scholar 

  190. Lee CS, Chen TL, Tzen CY, Lin FJ, Peng MJ, Wu CL, et al. Idiopathic inflammatory myopathy with diffuse alveolar damage. Clin Rheumatol. 2002;21(5):391–6. Epub 2002/09/12.

    PubMed  Google Scholar 

  191. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet. 1999;353(9166):1762–3. Epub 1999/05/29.

    CAS  PubMed Central  PubMed  Google Scholar 

  192. Bakewell CJ, Raghu G. Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest. 2011;139(2):441–3. Epub 2011/02/03.

    PubMed  Google Scholar 

  193. Vandenbroucke E, Grutters JC, Altenburg J, Boersma WG, ter Borg EJ, van den Bosch JM. Rituximab in life threatening antisynthetase syndrome. Rheumatol Int. 2009;29(12):1499–502. Epub 2009/02/03.

    CAS  PubMed  Google Scholar 

  194. Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford). 2009;48(8):968–71. Epub 2009/06/18.

    CAS  Google Scholar 

  195. Marie I, Dominique S, Janvresse A, Levesque H, Menard JF. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med. 2012;106(4):581–7. Epub 2012/01/28.

    CAS  PubMed  Google Scholar 

  196. Le Goff B, Cherin P, Cantagrel A, Gayraud M, Hachulla E, Laborde F, et al. Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis. Arthritis Rheum. 2009;61(1):108–18. Epub 2009/01/01.

    PubMed  Google Scholar 

  197. Minai OA. Pulmonary hypertension in polymyositis-dermatomyositis: clinical and hemodynamic characteristics and response to vasoactive therapy. Lupus. 2009;18(11):1006–10. Epub 2009/09/19.

    CAS  PubMed  Google Scholar 

  198. Cappelli S, Bellando Randone S, Martinovic D, Tamas MM, Pasalic K, Allanore Y, et al. “To be or not to be,” ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheumatism. 2012;41(4):589–98. Epub 2011/10/01, with permission from Elsevier [Reprint].

    Google Scholar 

  199. Prakash UB. Respiratory complications in mixed connective tissue disease. Clin Chest Med. 1998;19(4):733–46, ix. Epub 1999/01/26.

    CAS  PubMed  Google Scholar 

  200. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81. Epub 2010/09/28, Copyright © 2010 by the American College of Rheumatology [Reprint].

    PubMed  Google Scholar 

  201. Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, et al. American College of Rheumatology classification criteria for Sjogren’s syndrome: a data-driven, expert consensus approach in the Sjogren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res. 2012;64(4):475–87. Epub 2012/05/09, Copyright © 2012 by the American College of Rheumatology [Reprint].

    CAS  Google Scholar 

  202. Daniels TE, Cox D, Shiboski CH, Schiodt M, Wu A, Lanfranchi H, et al. Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjogren's syndrome among 1,726 registry participants. Arthritis Rheum. 2011;63(7):2021–30. Epub 2011/04/12.

    PubMed Central  PubMed  Google Scholar 

  203. Whitcher JP, Shiboski CH, Shiboski SC, Heidenreich AM, Kitagawa K, Zhang S, et al. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjogren's Syndrome International Registry. Am J Ophthalmol. 2010;149(3):405–15. Epub 2009/12/29.

    PubMed Central  PubMed  Google Scholar 

  204. Targoff IN, Miller FW, Medsger Jr TA, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1997;9(6):527–35. Epub 1998/02/12, with permission from Wolters Kluwer Health [Reprint].

    CAS  PubMed  Google Scholar 

  205. Kasukawa R, Sharp G. Diagnostic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp G, editors. Mixed connective tissue disease and antinuclear antibodies. Amsterdam: Elsevier Science Publishers B.V; 1987. p. 23–30.

    Google Scholar 

  206. Kasukawa R, Tojo T, Miyawaki S. Preliminary diagnostic criteria for classification of mixed connective tissue disease. In: Kasukawa R, Sharp G, editors. Mixed connective tissue disease and antinuclear antibodies. Amsterdam: Elsevier Science Publisher; 1987. p. 41–7.

    Google Scholar 

  207. Alarcon-Segovia D, Villareal M. Classification and diagnoctic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp G, editors. Mixed connective tissue disease and antinuclear antibodies. Amsterdam: Elsevier Science Publisher; 1987. p. 33–40.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de Pneumologie A, Hôpital Bichat-Claude Bernard, 16 rue Henri Huchard, Paris, 75877, France

    Bruno Crestani, Mathilde Neuville, Raphael Borie, Camille Taillé & Michel Aubier

  2. Service de Radiologie, Hôpital Bichat, Paris, France

    Marie-Pierre Debray

  3. Département d’anatomie-pathologique, Hôpital Bichat, Paris, France

    Claire Danel

  4. Laboratoire d’Explorations Fonctionnelles, Hôpital Bichat, Paris, France

    Laurent Plantier

Authors
  1. Bruno Crestani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marie-Pierre Debray
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claire Danel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mathilde Neuville
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Raphael Borie
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Camille Taillé
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Laurent Plantier
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Michel Aubier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bruno Crestani .

Editor information

Editors and Affiliations

  1. Rare Pulmonary Diseases, Hôpital Louis Pradel, Lyon, France

    Vincent Cottin

  2. Rare Pulmonary Diseases, Hôpital Louis Pradel, Lyon, France

    Jean-Francois Cordier

  3. Respiratory Medicine, University of Southampton, Southampton, United Kingdom

    Luca Richeldi

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag London

About this chapter

Cite this chapter

Crestani, B. et al. (2015). Interstitial Lung Disease in Connective Tissue Diseases Other Than Systemic Sclerosis. In: Cottin, V., Cordier, JF., Richeldi, L. (eds) Orphan Lung Diseases. Springer, London. https://doi.org/10.1007/978-1-4471-2401-6_26

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2401-6_26

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2400-9

  • Online ISBN: 978-1-4471-2401-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation